Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy

Emanuelle M. Rizk; Robyn D. Gartrell; Luke W. Barker; Camden L. Esancy; Grace G. Finkel; Darius D. Bordbar; Yvonne M. Saenger

doi:10.1016/j.hoc.2018.12.005

Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy

Emanuelle M. Rizk
, Robyn D. Gartrell
, Luke W. Barker
, Camden L. Esancy
, Grace G. Finkel
, Darius D. Bordbar
, Yvonne M. Saenger

Research output: Contribution to journal › Review article › peer-review

37 Scopus citations

Abstract

Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 ⁺ tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.

Original language	English (US)
Pages (from-to)	291-299
Number of pages	9
Journal	Hematology/Oncology Clinics of North America
Volume	33
Issue number	2
DOIs	https://doi.org/10.1016/j.hoc.2018.12.005
State	Published - Apr 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Checkpoint inhibition
Immunohistochemistry
Immunotherapy
Predictive and prognostic biomarkers

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2018.12.005

Cite this

@article{b7af228bc7e048488796adba9b5365fc,

title = "Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy",

abstract = " Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 + tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.",

keywords = "Checkpoint inhibition, Immunohistochemistry, Immunotherapy, Predictive and prognostic biomarkers",

author = "Rizk, \{Emanuelle M.\} and Gartrell, \{Robyn D.\} and Barker, \{Luke W.\} and Esancy, \{Camden L.\} and Finkel, \{Grace G.\} and Bordbar, \{Darius D.\} and Saenger, \{Yvonne M.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = apr,

doi = "10.1016/j.hoc.2018.12.005",

language = "English (US)",

volume = "33",

pages = "291--299",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy

AU - Rizk, Emanuelle M.

AU - Gartrell, Robyn D.

AU - Barker, Luke W.

AU - Esancy, Camden L.

AU - Finkel, Grace G.

AU - Bordbar, Darius D.

AU - Saenger, Yvonne M.

PY - 2019/4

Y1 - 2019/4

N2 - Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 + tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.

AB - Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 + tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.

KW - Checkpoint inhibition

KW - Immunohistochemistry

KW - Immunotherapy

KW - Predictive and prognostic biomarkers

UR - https://www.scopus.com/pages/publications/85060116071

UR - https://www.scopus.com/pages/publications/85060116071#tab=citedBy

U2 - 10.1016/j.hoc.2018.12.005

DO - 10.1016/j.hoc.2018.12.005

M3 - Review article

C2 - 30833001

AN - SCOPUS:85060116071

SN - 0889-8588

VL - 33

SP - 291

EP - 299

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 2

ER -

Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this